Article

Robert W. Dubois, MD, PhD, Describes the Initial Expectations of Accountable Care Organizations

Conference|AMCP: The Academy of Managed Care Pharmacy

Robert W. Dubois, MD, PhD, the chief science officer of the National Pharmaceutical Council discusses the initial expectations of implementing accountable care organizations (ACOs) and how those expectations have evolved over time.

Robert W. Dubois, MD, PhD, the chief science officer of the National Pharmaceutical Council discusses the initial expectations of implementing accountable care organizations (ACOs) and how those expectations have evolved over time.

This video was taken at the Academy of Managed Care Pharmacy's 25th Annual Meeting & Expo in San Diego, CA, on April 4, 2013.

Related Videos
Marla Black Morgan, MD, Phoebe Neurology Associates
Toby Maher, MD, PhD, professor of clinical medicine, Keck School of Medicine at USC
Nini Wu, MD, Navista
Matthew Viggiano, MD, internal medicine resident, Temple University Hospital
Krunal Patel, MD, pulmonary and critical care fellow, Temple University Hospital
M. Bradley Drummond, MD, MHS, professor of medicine, University of North Carolina at Chapel Hill
Sanjay Ramakrishnan, MD, senior lecturer, University of Western Australia
Michael Goulet, DO, pulmonary and critical care fellow, Temple University Hospital
Tom Belmon, CAP, GPBCH
Tom Belmont
Related Content
ASCO Guidelines | Image: ASCO
May 21st 2025

ASCO, Google Cloud Launch AI-Powered Tool to Help Doctors Access Guidelines

Mary Caffrey
The artificial intelligence-powered assistant will save clinicians time, especially in busy settings in community oncology.
AJMC Managed Care Cast
December 31st 2024

AJMC® Editors Reflect on 2024 and Look Forward to a Milestone

Christina Mattina
The editors in chief of The American Journal of Managed Care® discuss the key managed care research and news from 2024 and look forward to the journal’s upcoming 30th anniversary.
Pill and water in hand | Image credit: New Africa – stock.adobe.com
May 20th 2025

FIBRONEER-ILD: Novel PDE4B Inhibitor Slows FVC Decline in Progressive Pulmonary Fibrosis

Hayden E. Klein
Nerandomilast significantly slowed lung function decline and reduced mortality in patients with progressive pulmonary fibrosis (PPF), with consistent efficacy regardless of background antifibrotic therapy.
Managed Care Cast logo
April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
IPF letter blocks | Image credit: surasak – stock.adobe.com
May 19th 2025

Nerandomilast Slows Lung Function Decline in Patients With IPF

Hayden E. Klein
The latest results from the phase 3 FIBRONEER-IPF trial showed consistent benefit of nerandomilast in patients with idiopathic pulmonary fibrosis (IPF) whether or not they were receiving background antifibrotic therapy.
Doctor checking on sleeping patient in ICU | Image credit: Gorodenkoff – stock.adobe.com
May 19th 2025

Sleep Patterns, Predictors, and Pharmacologic Interventions in the ICU

Hayden E. Klein
Research presented at the American Thoracic Society (ATS) 2025 International Conference used FDA-approved tools to see how sleep can impact other parts of recovery for patients in the intensive care unit (ICU).

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo